Gornoslaskie Centrum Zdrowia Dziecka Im. Sw. Jana Pawla II Samodzielny Publiczny Szpital Kliniczny Nr 6 Slaskiego Uniwersytetu Medycznego W Katowicach
- Address
- lock Available on a paid plan
Gornoslaskie Centrum Zdrowia Dziecka - Pediatric Clinical Research Center
The Gornoslaskie Centrum Zdrowia Dziecka Im. Sw. Jana Pawla II, affiliated with the Medical University of Silesia in Katowice, is a leading pediatric clinical research institution specializing in advanced therapeutic interventions for complex childhood diseases. The center demonstrates exceptional expertise in pediatric oncology, autoimmune disorders, and innovative cell-based therapies, conducting cutting-edge multinational trials that push the boundaries of pediatric medicine.
- Pediatric hematologic malignancies, including acute lymphoblastic leukemia, lymphoblastic lymphoma, and myeloid leukemia in children with Down syndrome
- Advanced immunotherapy and cell therapy for Type 1 diabetes, including regulatory T-cell therapy and novel biologics like teplizumab
- Pediatric inflammatory bowel disease research, focusing on moderate to severe Crohn's disease and ulcerative colitis
- Rare pediatric cancers, including hepatoblastoma and hepatocellular carcinoma
The center participates in prestigious international collaborative protocols such as AIEOP-BFM studies for leukemia and the Paediatric Hepatic International Tumour Trial. Their research portfolio includes phase II and III randomized controlled trials evaluating novel targeted therapies, immunomodulatory agents, and combination treatment regimens designed specifically for pediatric populations, with a strong emphasis on improving survival rates while minimizing treatment-related toxicities in vulnerable young patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 7 therapeutic areas and 15 of 60 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 60 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gornoslaskie Centrum Zdrowia Dziecka Im. Sw. Jana Pawla II Samodzielny Publiczny Szpital Kliniczny Nr 6 Slaskiego Uniwersytetu Medycznego W Katowicach
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 60 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 6 | Unknown | 2019-08-01 | 2024-11-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.